Canopy Growth (CGC) Income from Continuing Operations (2019 - 2025)
Canopy Growth (CGC) reported Income from Continuing Operations of 77577262.44 for Q4 2025, down 10.49% on a YoY basis from 86667892.64 in Q4 2024, and down 2044.68% sequentially from 3617189.04 in Q3 2025.
Canopy Growth (CGC) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Income from Continuing Operations data on file, last reported at 77577262.44 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 10.49% year-over-year to 77577262.44; the trailing twelve-month figure through Dec 2025 stood at 183783827.17 (up 46.47% YoY), and the FY2026 full-year result was 191744636.7, down 173.54% from the prior year.
- Income from Continuing Operations retreated to 77577262.44 in Q4 2025, from 3617189.04 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 317238982.72 in Q2 2021 to a low of 1640644562.36 in Q2 2022.
- A 5-year average of 147661271.75 and a median of 82263253.69 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 442.79% in 2021 and tumbled 1061.13% in 2022, its largest moves.
- Tracing CGC's Income from Continuing Operations over 5 years: stood at 91627144.08 in 2021, then tumbled by 82.39% to 167116641.72 in 2022, then rose by 3.68% to 160968319.01 in 2023, then soared by 56.38% to 70212631.25 in 2024, then decreased by 10.49% to 77577262.44 in 2025.
- Business Quant data shows CGC's Income from Continuing Operations at 77577262.44 in Q4 2025, 3617189.04 in Q3 2025, and 32376744.43 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -77.58 Mn |
| Sep 30, 2025 | -3.62 Mn |
| Jun 30, 2025 | -32.38 Mn |
| Dec 31, 2024 | -70.21 Mn |
| Sep 30, 2024 | -82.26 Mn |
| Jun 30, 2024 | -78.91 Mn |
| Mar 31, 2024 | -111.94 Mn |
| Dec 31, 2023 | -160.97 Mn |
| Sep 30, 2023 | -104.09 Mn |
| Jun 30, 2023 | -7.87 Mn |
| Mar 31, 2023 | 165.78 Mn |
| Dec 31, 2022 | -167.12 Mn |
| Sep 30, 2022 | -150.64 Mn |
| Jun 30, 2022 | -1.64 Bn |
| Mar 31, 2022 | -408.19 Mn |
| Dec 31, 2021 | -91.63 Mn |
| Sep 30, 2021 | -12.97 Mn |
| Jun 30, 2021 | 317.24 Mn |
| Mar 31, 2021 | -87.57 Mn |
| Dec 31, 2020 | -636.08 Mn |